0000899243-20-017706.txt : 20200625
0000899243-20-017706.hdr.sgml : 20200625
20200625200110
ACCESSION NUMBER: 0000899243-20-017706
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200625
FILED AS OF DATE: 20200625
DATE AS OF CHANGE: 20200625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC
CENTRAL INDEX KEY: 0001055951
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39344
FILM NUMBER: 20990637
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: OrbiMed Capital GP VII LLC
CENTRAL INDEX KEY: 0001760648
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39344
FILM NUMBER: 20990638
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 212-739-6491
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fusion Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001805890
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
BUSINESS PHONE: 289-799-0891
MAIL ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-06-25
0
0001805890
Fusion Pharmaceuticals Inc.
FUSN
0001055951
ORBIMED ADVISORS LLC
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK
NY
10022
1
0
0
0
0001760648
OrbiMed Capital GP VII LLC
501 LEXINGTON AVE, 54TH FLOOR
NEW YORK
NY
10022
1
0
0
0
Class B Preferred Shares
Common Shares
2224770
I
By OrbiMed Private Investments VII, LP
Warrants to purchase Class B Preferred Shares
8.10
2020-01-10
2022-01-10
Common Shares
67311
I
By OrbiMed Private Investments VII, LP
The Class B Preferred Shares are convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, the Class B Preferred Shares will convert into the number of Common Shares shown in column 3. The Class B Preferred Shares have no expiration date.
These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VII.
This report on Form 3 is jointly filed by GP VII and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Chau Khuong, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares will become warrants to purchase Common Shares at an exercise price of $8.10 per share.
OrbiMed Advisors LLC, By: /s/ Douglas Coon, Name: Douglas Coon, Title: Chief Compliance Officer
2020-06-25
OrbiMed Capital GP VII LLC, By: /s/ Douglas Coon, Name: Douglas Coon, Title: Chief Compliance Officer
2020-06-25